Nov 12, 2018 8:04:00 AM
In this blog, we talk with Robert Greene, Founder and President of the HungerNDThirst Foundation, about his upcoming presentation at Cytel’s East User Group Meeting on 14th and 15th November at Merck in Darmstadt, Germany. Robert will bring a fresh perspective to the discussion of the role statisticians can play in enhancing the position of patients in clinical trials. Patient-centricity is a...
Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, biostatistics, Statistical Innovations in Clinical Development, randomization, patientricity
Oct 18, 2018 11:09:00 AM
In this blog, we talk with Simon Kirby, former Senior Director at Pfizer, about his upcoming presentation at Cytel’s East User Group Meeting on 14th and 15th November at Merck Darmstadt, in Germany. Simon will address the topic of Selection Bias for Treatments with Positive Phase 2 Results and in this blog he explains why this is a key topic of particular relevance for pharmaceutical companies...
Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, go-no-go, biostatistics, Statistical Innovations in Clinical Development, randomization
Oct 5, 2018 7:00:00 AM
We are delighted that Stephen Senn will be joining us at the EUGM on November 14th and 15th in Darmstadt, Germany. In this blog, we sit down for a discussion with Stephen about his career in statistics, his advice for early career statisticians, his upcoming research, and the topic of his presentation at the East User Group Meeting “70 Years Old and Still Here: the Randomized Clinical Trial...
Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, go-no-go, biostatistics, Statistical Innovations in Clinical Development, randomization
Sep 27, 2018 9:00:00 AM
In this blog, we talk with Heiko Götte, Senior Expert Biostatistician at Merck about his upcoming presentation at Cytel’s East User Group Meeting on 14th and 15th November at Merck Darmstadt, in Germany. The topic Heiko will address is Decision Making in Development Programs with Targeted Therapies and he explains to us why this is a key topic for pharmaceutical companies today as they...
Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, Biomarkers, go-no-go
Aug 15, 2018 6:08:00 AM
Cytel’s 7th East User Group Meeting (EUGM) will take place on November 14 & 15, 2018 at Merck in Darmstadt, Germany, bringing together industry experts, thought leaders and applied statisticians to discuss the future of clinical trials.
The agenda has been developed collaboratively by the EUGM Scientific Committee, and keynote speakers will include Stephen Senn, Meinhard Kieser, Thomas...
Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods
May 30, 2017 8:06:00 AM
A recent paper The case for Bayesian methods in benefit-risk assessment: Overview and future directions (1) co-authored by Cytel Senior Vice President Consulting Yannis Jemiai and published in Therapeutic Innovation and Regulatory Science, tackles the critical issue of benefit risk assessment, and the part Bayesian approaches can play in resolving their challenges.
There is certainly an...
Topics: biostatistics, benefit risk assessment, Statistical Analysis, Bayesian Methods, Bayesian
Mar 24, 2017 9:27:00 AM
Robust go/no-go (GNG) decision-making is essential for effectively managing risk across a clinical portfolio. In early phase development, it is particularly important to have the correct tools in place to terminate ineffective compounds quickly, while accelerating promising ones through the process.
Topics: biostatistics, custom software, go-no-go, Bayesian, Bayesian Methods, Case Study
Mar 2, 2017 8:45:00 AM
We continue our case study series with this example of a Phase 3 design that uses Bayesian decision making combined with frequentist final analysis.
Clinical Development Background
Our biopharmaceutical client’s lead drug candidate is a late clinical-stage cancer immunotherapy for treatment of a rare oncology indication. Clinical development of therapies in this indication faces inherent...
Topics: biostatistics, adaptive trials, adaptive sample size re-estimation, Bayesian Methods, Bayesian, Oncology, Phase 3
Jul 21, 2016 6:30:00 AM
Did you miss our webinar on Single and Dual Agent Dose escalation designs earlier in the year? In this blog we have made the replay available for your review, and also take the opportunity to recap key reasons why you should consider a model based design for your dose escalation study.
Topics: Oncology, Dose-Escalation, Bayesian Methods, EAST 6.4
May 31, 2016 7:30:00 AM
Last week, we were delighted to announce the release of East 6.4 bringing further cutting –edge approaches to the East user community. East is the industry standard platform for clinical trial design, simulation, and monitoring, improving scientific productivity during the critical planning stages of clinical development. In this blog we catch up with Yannis Jemiai, VP of Cytel to gain some...
Topics: East, Bayesian Methods, East PREDICT, Prediction, Software Simulations, Multi-Arm Studies, Multi-Arm Multi-Stage Studies, biostatistics, EAST 6.4, adaptive trials
May 19, 2016 6:00:00 AM
The explosion in healthcare information and “big data “has been one of the most written about topics in the last few years. These big data in the form of electronic health records, diagnostic tests, genomics, proteomics, not to mention data from wearable devices and apps have the potential to transform healthcare. That potential can only be realized though through the application of advanced...
Topics: Bayesian Methods, Computing, Clinical Data, biostatistics, machine learning, big data, pattern recognition
Mar 29, 2016 11:00:00 AM
On March 16th and 17th the 5th East User Group Meeting took place in London. This very successful 2 days saw a variety of talks on aspects of clinical trial design innovation. Over the next couple of weeks, we will be reviewing some of the key topics which were addressed during the meeting.
In this post, we'll take a look at Paul Frewer of Astrazeneca's presentation on Decision Making in...
Topics: Bayesian Methods, Cytel Consulting, Cytel Videos, Phase 1, Early Phase Trials, phase 2
Mar 23, 2016 9:30:00 AM
“How many statisticians does it take to ensure at least a 50% chance of a disagreement about p-values?”
So questions George Cobb of Mt. Holyoke College in his commentary on the ASA’s 7th March ‘Statement on P Values: context, process and purpose’
The association took the unprecedented step of publishing the statement following a long litany of criticism of misuse of the P value. This included...
Topics: Bayesian Methods, p value
Nov 12, 2015 4:00:00 PM
Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods in early phase oncology. Patrick Mitchell, an Associate Director of Statistical Sciences at Astra Zeneca, gave this talk on Bayesian go/no-go decision-making in an early phase oncology event study.
Astra Zeneca recently invited Cytel to take part in a collaborative initiative...
Topics: Bayesian Methods, Early Phase Trials, Clinical Development Strategy, go-no-go
Nov 10, 2015 4:00:00 PM
Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods in early phase oncology.
Topics: Dose-Escalation, Bayesian Methods
Oct 27, 2015 6:04:00 PM
Here at Cytel we have enjoyed following the debates on the p-value controversy currently taking place on the ASA website, and indeed debating the issue ourselves. While we plan to post our views on the topic in the weeks to come, we would like to invite your thoughts on the issue as well.
Topics: Bayesian Methods, Statistical Analysis
Sep 15, 2015 3:56:42 PM
Topics: Bayesian Methods, Cytel Consulting, Case Study, Adaptive Clinical Trials
Sep 1, 2015 4:01:39 PM
If you’re in the practice of conducting early phase clinical trials, you’ve probably heard that modern trial designs include a number of new methodologies. There’s CRM and BLRM, model-based methods versus rule-based methods, and a number of other developments that might affect your clinical strategy. Each of these methods affects operational, financial and regulatory objectives in unique ways.
As...
Topics: Bayesian Methods, CRM, Early Phase Trials, Clinical Development Strategy, BLRM
Jul 10, 2015 12:54:00 PM
Here at Cytel, we are engaging in a small celebration this afternoon, as the US House of Representatives has just passed the FDA Reform Bill more generally known as the 21st Century Cures Act.
Although this bill is widely viewed as a reform bill, it will provide extensive funding to both the FDA and NIH to ensure that clinical and pharmaceutical research lives up to its potential to deliver...
Topics: Bayesian Methods, Regulation, Medical Devices, Adaptive Clinical Trials
Mar 20, 2015 4:29:00 PM
Sometimes a new candidate drug for a pediatric study has already been tested on adults for safety and efficacy. We know that the drug is likely to work quite differently in children, but we do not know the degree to which the effects will be different. As a result, a conventional approach is to discard much of the information that has already gathered during studies of adults, and then to start...
Topics: Bayesian Methods, Adaptive Clinical Trials, Pediatric